Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study
Saved in:
| Title: | Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study |
|---|---|
| Authors: | D'Angelo, Salvatore1 (AUTHOR) saldangelo@katamail.com, Tirri, Enrico2 (AUTHOR), Giardino, Angela Maria3 (AUTHOR), De Rosa, Tiziana3 (AUTHOR), Matucci‐Cerinic, Marco4,5 (AUTHOR), Dagna, Lorenzo5 (AUTHOR), Santo, Leonardo6 (AUTHOR), Ciccia, Francesco7 (AUTHOR), Frediani, Bruno8 (AUTHOR), Govoni, Marcello9 (AUTHOR), Pallavicini, Francesca Bobbio10 (AUTHOR), Grembiale, Rosa Daniela11 (AUTHOR), Sedie, Andrea Delle12 (AUTHOR), Mulè, Rita13 (AUTHOR), Cantatore, Francesco Paolo14 (AUTHOR), Foti, Rosario15 (AUTHOR), Gremese, Elisa16 (AUTHOR), Conigliaro, Paola17 (AUTHOR), Salaffi, Fausto18 (AUTHOR), Viapiana, Ombretta19 (AUTHOR) |
| Source: | International Journal of Rheumatic Diseases. Mar2024, Vol. 27 Issue 3, p1-7. 7p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
